GPGerentes Philippe

Gerentes Philippe

*This is an algorithmically generated author record based on publicly available information.

Gerentes Philippe has a total of 3 co-authors. Here are the top co-authors by number of shared publications:

  • Chaufferin Gilles

    Allyane

    1 shared publication
  • Remillieux Franck

    Private Practice

    1 shared publication
  • Typhanie Dos Anjos

    Unité de Formation et de Recherche en Activités Physiques et Sportives, Université de Lyon, Université Lyon 1, Laboratoire Interuniversitaire de Biologie de la Motricité-EA 7424, UFRSTAPS, Villeurbanne Cedex, France; Allyane®, 84 quai Joseph Gillet, 69004 Lyon, France

    1 shared publication

Latest Publications

  • Open Access

    A novel neuromotor reprogramming treatment modality for temporomandibular disorders: a pilot retrospective observational study

    by Remillieux Franck, Typhanie Dos Anjos, Chaufferin Gilles, Gerentes Philippe

    Background The purpose of this investigation was to determine if neuromotor programming using the ALLYANE® process would significantly improve mouth-opening capacity in patients suffering from temporomandibular disorders (TMD). Methods A total of 21 adult patients (20 females and 1 male; mean age = 44 years) who underwent a rehabilitation session with neuromotor reprogramming were included. Maximal mouth opening (MMO) was measured before and just after neuromotor reprogramming session. Results The results showed a statistically significant (p < 0.001) mean gain of 4.95 mm (+ 13%) after neuromotor reprogramming. Furthermore, this preliminary study showed that the gain registered in patients with a lower-than-normal mouth opening and improvement of lateral movements were greater than the one obtained with the other patients. Conclusions Although these preliminary results need confirmation, the study suggests that the use of neuromotor reprogramming in patients suffering from TMD could present new possibilities for enhanced outcomes, in particular to relax the stomatognathic system with a noninvasive, reversible therapy without known side effects, providing open new perspectives in the area of joint diseases.